No public English COA is assigned to this specification yet.
COA · ENGLISH · RT5The public COA is shown in English and kept in its original laboratory form. Internal self-inspection COAs are private.
Fat loss & metabolism
Retatrutide research material is available in 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg. Select the required specification below. The displayed amount is the price per vial; orders start at 10 vials and increase in multiples of 10.
Retatrutide research material is available in 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg. Select the required specification below. The displayed amount is the price per vial; orders start at 10 vials and increase in multiples of 10.
LYSENTA research catalogue
Description
Retatrutide research material is available in 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg. Select the required specification below. The displayed amount is the price per vial; orders start at 10 vials and increase in multiples of 10.
Supplied strictly as laboratory research material. Record the selected SKU, batch and COA in the research workflow.
Frequently asked questions
The displayed price is per vial. The spreadsheet box price has been divided by 10 without changing its total: selecting 10 vials equals one full box.
The minimum is 10 vials, and every additional quantity must be a multiple of 10.
When available, the public English COA is linked to the selected specification. Internal self-inspection COAs remain private in the administration area.
This material is supplied strictly for laboratory and research use and is not intended for human or animal use.
RESEARCH & QUALITY DOCUMENTATION
Content updated · English reference edition
Retatrutide is studied as an agonist at three receptors: GIP, GLP-1 and glucagon. That receptor combination distinguishes it from dual incretin agonists and single GLP-1 receptor agonists. This page brings together the available LYSENTA specifications, public analytical documents and a starting point for reviewing the scientific literature. Research material listed here is not a clinical trial formulation or a medicine for personal use.
Human trial — investigational formulation, not this catalogue material
A randomized phase 2 trial published by Jastreboff and colleagues in 2023 investigated retatrutide in adults with obesity. It is human clinical evidence about an investigational formulation under a defined protocol, not validation of a third-party research vial. A clinical publication cannot establish this catalogue product's identity, potency, sterility or suitability for administration. Use the paper to understand the research question and its limits, and use the actual batch documentation to assess material identity.
Reference: Jastreboff et al., 2023 — phase 2 retatrutide trial (NEJM) ↗
Compare the complete chemical identity and batch identifiers, not just the word retatrutide. A report for another incretin agonist, a blend or a different specification is not interchangeable. When comparing receptor studies, check the assay system, comparator and reported endpoint before interpreting apparent differences.
For a retatrutide research enquiry, specify the catalogue SKU and required quantity, then ask which batch will be supplied. Match any analytical report to that exact material. Request the identity method, chromatographic method and reported sample identifier; a headline purity percentage alone does not describe all quality attributes.
Retatrutide research involves GIP, GLP-1 and glucagon receptor agonism; tirzepatide research concerns GIP and GLP-1. Different targets do not establish that one catalogue material is better or suitable for a particular person.
No. Published studies concern the material and conditions used by their investigators. Product-specific identity and analytical quality must be assessed from the supplied batch documentation.
Choose a specification in the product selector and review its COA panel. A pending-upload notice means a public document has not been assigned there; it is not a substitute for a report.
Sources describe the materials and conditions studied by their authors. They are not endorsements of LYSENTA or certificates for the products on this website.
Related does not mean interchangeable. Check composition and evidence separately.
Browse all research and documentation guides →
For laboratory research only. Not for human or animal use. No clinical dosing, treatment or administration advice is provided.
SAME CATEGORY
